Documentation of adverse effects in the second cohort receiving the intermediate dose of peptide-loaded tolDC

Adverse events will be summarized by presenting for each cohort, the number and proportion of patients having any adverse event. All AE and special reporting situations, whether serious or non-serious, occurring during the study will be reported to the data and safety monitoring board by study-site personnel within 24 hours of their knowledge of the event. The investigators will report these events to the regulatory authorities and the independent ethics committee that approved the protocol.